Bionova Scientific aims to quadruple GMP biologics manufacturing capacity

By Jane Byrne

- Last updated on GMT

© GettyImages/Khanchit Khirisutchalual
© GettyImages/Khanchit Khirisutchalual

Related tags Monoclonal antibodies

The project is the first phase of a wider strategic initiative to expand capacity and enhance end-to-end biologics development and manufacturing services at the US CDMO.

Bionova Scientific has commenced commissioning of a third facility in Fremont, California, which it said will enable a significant scale-up of its manufacturing capacity and service capabilities.

The expansion, it said, also marks the start of a long-term strategic initiative by the company, which was founded in 2014, to broaden its services portfolio to cover an even wider range of technical capabilities and therapeutic modalities, in response to diversifying customer requests.

Acquired by the Asahi Kasei Group​ in 2022, Bionova Scientific is a full-service biologics contract development and manufacturing organization (CDMO). It says its operations are optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins.   

Manufacturing and development footprint 

It currently operates two facilities in Fremont: a headquarters and development and GMP manufacturing facility on West Warren Avenue, and a nearby dedicated warehouse and storage facility on Fremont Boulevard.

The new Laurelview facility will act as a replacement headquarters and development center, housing Bionova Scientific’s administrative functions and biologics development teams that are currently located in the West Warren facility. In turn, the West Warren facility will become devoted to manufacturing operations, using advanced single-use equipment systems. The administrative offices and the labs for cell line development, process development and analytical services are expected to be moved to the Laurelview facility in mid-2023, ensuring the CDMO can quadruple its current biologics GMP manufacturing capacity in the West Warren facility shortly thereafter.

Darren Head, CEO of Bionova Scientific, said the cell line development, process development and analytical services teams will each have more capacity and resources for development projects, while increasing the GMP manufacturing footprint in the West Warren facility means the CDMO can provide more manufacturing slots to clinical and commercial customers to help them meet their timelines.

Related topics Markets & Regulations Facilities

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more